William Fry LLP has long been a force in corporate transactions, including private and public M&A. In recent times, it has advised on a number of the largest M&A and private equity deals in the market, including Amgen’s headline acquisition of Horizon Therapeutics. The firm has a history of transactions in the healthcare and life sciences, TMT, energy and renewables, financial services and insurance, and real estate sectors. It has also advised on a series of transactions in the data centre sector. Department head Stephen Keogh and public takeovers leader Myra Garrett are top practitioners, along with energy transactions expert Máire O’Neill and technology and life sciences specialist Andrew McIntyre . Mark Talbot is rated for public M&A, while Brian Butterwick has extensive international connections and Mark Quealy brings further expertise in life sciences, private equity and venture capital.
Legal 500 Editorial commentary
Profile
Work Department
Corporate and M&A; Equity Capital Markets
Position
Stephen Keogh is the Managing Partner of William Fry. Stephen was previously Head of William Fry’s Corporate/M&A department specialising in transactional corporate work with a particular emphasis on private equity transactions, acting for sponsors, target companies and management teams.
Stephen served on William Fry’s management committee for 3 years and was head of William Fry’s London office for 5 years.
Content supplied by William Fry LLP
Key clients
- Echelon Data Centres
- Amgen Inc
- Uniphar
- JOLT
- Department of Finance
- DCC
- Tines
- Irish Rugby Football Union
- UKG Group
- J&E Davy
Work highlights
Advised Amgen on its acquisition of Horizon Therapeutics.
Advised the Department of Finance on the directed buyback by AIB Group from the Minister for Finance.
Advised Echelon Data Centres on the strategic investment in the company by Starwood Capital Group.